• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤微环境对检查点阻断治疗的贡献：霍奇金淋巴瘤的经验教训。

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma.

机构信息

Department of Pathology, Centro di Riferimento Oncologico Aviano, Istituto Nazionale Tumori, IRCCS, Aviano, Italy.

Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.

出版信息

Blood. 2023 May 4;141(18):2187-2193. doi: 10.1182/blood.2022016590.

DOI:10.1182/blood.2022016590
PMID:36898085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10646787/
Abstract

Classic Hodgkin lymphoma (cHL) is characterized by a tumor microenvironment (TME) containing inflammatory/immune cells. Follicular lymphoma, mediastinal gray zone lymphoma, and diffuse large B-cell lymphomas may show a TME containing inflammatory/immune cells, but the TMEs are quite different. In B-cell lymphomas and cHL, programmed cell death 1 (PD-1)-PD ligand 1 pathway blockade drugs differ in their effectiveness among patients with refractory/relapsed disease. Further research should explore innovative assays that could reveal which molecules influence sensitivity or resistance to therapy in an individual patient.

摘要

经典型霍奇金淋巴瘤（cHL）的特征是肿瘤微环境（TME）中含有炎症/免疫细胞。滤泡性淋巴瘤、纵隔灰区淋巴瘤和弥漫性大 B 细胞淋巴瘤也可能表现出含有炎症/免疫细胞的 TME，但 TME 有很大的不同。在 B 细胞淋巴瘤和 cHL 中，程序性细胞死亡 1（PD-1）-PD 配体 1 通路阻断药物在难治/复发疾病患者中的疗效存在差异。进一步的研究应探索创新的检测方法，以揭示哪些分子会影响个体患者对治疗的敏感性或耐药性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/266b/10646787/a361524c1585/BLOOD_BLD-2022-016590-C-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/266b/10646787/856706e47909/BLOOD_BLD-2022-016590-C-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/266b/10646787/7ddb4d95ab99/BLOOD_BLD-2022-016590-C-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/266b/10646787/a361524c1585/BLOOD_BLD-2022-016590-C-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/266b/10646787/856706e47909/BLOOD_BLD-2022-016590-C-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/266b/10646787/7ddb4d95ab99/BLOOD_BLD-2022-016590-C-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/266b/10646787/a361524c1585/BLOOD_BLD-2022-016590-C-gr2.jpg

相似文献

1
Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma.肿瘤微环境对检查点阻断治疗的贡献：霍奇金淋巴瘤的经验教训。
Blood. 2023 May 4;141(18):2187-2193. doi: 10.1182/blood.2022016590.
2
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.PD-1/PD-L1 通路及其阻断在经典霍奇金淋巴瘤和非霍奇金大细胞淋巴瘤患者中的作用。
Curr Hematol Malig Rep. 2020 Aug;15(4):372-381. doi: 10.1007/s11899-020-00589-y.
3
Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?原发性纵隔大 B 细胞淋巴瘤、纵隔经典霍奇金淋巴瘤和纵隔灰区淋巴瘤：肿瘤学家该如何处理？
Curr Hematol Malig Rep. 2011 Sep;6(3):157-63. doi: 10.1007/s11899-011-0090-1.
4
Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.纵隔大 B 细胞淋巴瘤及周围灰区：欧洲血液病理学协会第 20 次会议淋巴瘤研讨会报告。
Virchows Arch. 2023 Dec;483(6):733-749. doi: 10.1007/s00428-023-03550-5. Epub 2023 Aug 2.
5
Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma.纵隔 B 细胞淋巴瘤的比较病理学分析：p63 的选择性表达但 GATA3 不表达可最佳地区分原发性纵隔大 B 细胞淋巴瘤与经典霍奇金淋巴瘤。
Diagn Pathol. 2019 Dec 12;14(1):133. doi: 10.1186/s13000-019-0918-x.
6
Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities.霍奇金淋巴瘤及相关实体瘤的定义与诊断进展
Virchows Arch. 2023 Jan;482(1):207-226. doi: 10.1007/s00428-022-03427-z. Epub 2022 Oct 24.
7
GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.GATA3免疫组织化学染色在霍奇金淋巴瘤中的应用：在鉴别经典型霍奇金淋巴瘤与结节性淋巴细胞为主型霍奇金淋巴瘤及其他相似病变中的诊断价值
Appl Immunohistochem Mol Morphol. 2019 Mar;27(3):180-184. doi: 10.1097/PAI.0000000000000581.
8
J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.J链和肌细胞增强因子2B有助于鉴别经典型霍奇金淋巴瘤与结节性淋巴细胞为主型霍奇金淋巴瘤以及原发性纵隔大B细胞淋巴瘤。
Hum Pathol. 2017 Oct;68:47-53. doi: 10.1016/j.humpath.2017.08.015. Epub 2017 Aug 26.
9
Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.纵隔灰色地带淋巴瘤：经典霍奇金淋巴瘤与纵隔大B细胞淋巴瘤之间缺失的环节。
Am J Surg Pathol. 2005 Nov;29(11):1411-21. doi: 10.1097/01.pas.0000180856.74572.73.
10
The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma.CD83、 fascin 和 CD23 在原发性纵隔大 B 细胞淋巴瘤与经典霍奇金淋巴瘤鉴别诊断中的应用。
Ann Diagn Pathol. 2019 Jun;40:72-76. doi: 10.1016/j.anndiagpath.2019.04.009. Epub 2019 Apr 23.

引用本文的文献

1
Hodgkin Lymphoma Classification-From Historical Concepts to Current Refinements.霍奇金淋巴瘤分类——从历史概念到当前的细化
Cancers (Basel). 2025 Sep 7;17(17):2929. doi: 10.3390/cancers17172929.
2
Topological importance of CD8 T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma.经典型霍奇金淋巴瘤肿瘤微环境中CD8 T细胞富集的拓扑学重要性。
Ann Hematol. 2025 Feb;104(2):1047-1057. doi: 10.1007/s00277-025-06189-1. Epub 2025 Jan 17.
3
Pathobiological Features and Therapeutic Opportunities Linked to TNF Family Member Expression in Classic Hodgkin Lymphoma.

本文引用的文献

1
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版：淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
2
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.成熟淋巴细胞肿瘤国际共识分类：临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
3
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
与经典型霍奇金淋巴瘤中TNF家族成员表达相关的病理生物学特征及治疗机会
Cancers (Basel). 2024 Dec 5;16(23):4070. doi: 10.3390/cancers16234070.
4
In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869.在多柔比星适应的霍奇金淋巴瘤细胞中，获得多药耐药性和改善的免疫抑制能力后，氯喹和 GW4869 增强了多柔比星的活性。
Cells. 2023 Nov 29;12(23):2732. doi: 10.3390/cells12232732.
复发/难治性霍奇金淋巴瘤中PD-1抑制剂治疗后进行化疗的疗效及克隆进化动态
Br J Haematol. 2022 Jul;198(1):82-92. doi: 10.1111/bjh.18183. Epub 2022 Apr 25.
4
The Grey Zones of Classic Hodgkin Lymphoma.经典型霍奇金淋巴瘤的灰色地带
Cancers (Basel). 2022 Jan 31;14(3):742. doi: 10.3390/cancers14030742.
5
Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression.针对巨噬细胞以增强 CD47 阻断引发的淋巴瘤清除并克服肿瘤诱导的免疫抑制。
Blood. 2022 Jun 2;139(22):3290-3302. doi: 10.1182/blood.2021013901.
6
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions.弥漫性大B细胞淋巴瘤的免疫疗法：现状与未来方向
Cancers (Basel). 2021 Nov 20;13(22):5827. doi: 10.3390/cancers13225827.
7
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.帕博利珠单抗联合吉西他滨、长春瑞滨和脂质体多柔比星作为二线治疗复发或难治性经典型霍奇金淋巴瘤的 II 期临床试验。
J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25.
8
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.本妥昔单抗联合纳武单抗治疗复发或难治性霍奇金淋巴瘤：3年研究结果
Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178.
9
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.抗 PD-1 治疗后自体干细胞移植治疗多发性复发或难治性霍奇金淋巴瘤。
Blood Adv. 2021 Mar 23;5(6):1648-1659. doi: 10.1182/bloodadvances.2020003556.
10
Molecular biology of Hodgkin lymphoma.霍奇金淋巴瘤的分子生物学。
Leukemia. 2021 Apr;35(4):968-981. doi: 10.1038/s41375-021-01204-6. Epub 2021 Mar 8.